Jump to content

PL-6983

From Wikipedia, the free encyclopedia
PL-6983
Clinical data
Routes of
administration
Subcutaneous injection
Drug classMelanocortin MC4 receptor agonist
Identifiers
CAS Number
PubChem SID

PL-6983 is a synthetic peptide and selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction.[1][2] It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials.[1][2] Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models.[1][2] The drug has reportedly been in pre-clinical development for all medical indications since 2008.[3] Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983."[4] The chemical structure of PL-6983 has yet to be made public.

See also

[edit]

References

[edit]
  1. ^ a b c Simon JA (July 2009). Mitchner N (ed.). "Opportunities for intervention in HSDD" (PDF). The Journal of Family Practice. 58 (7 Suppl Hypoactive): S26–30. PMID 19825316. Archived from the original (PDF) on 2015-05-18. Retrieved 2015-05-14.
  2. ^ a b c Krychman ML, Finestone S (25 October 2010). 100 Questions & Answers About Breast Cancer Sensuality, Sexuality and Intimacy. Jones & Bartlett Publishers. pp. 120–. ISBN 978-1-4496-1936-7.
  3. ^ "Research programme: sexual dysfunction therapy - Palatin Technologies". AdisInsight. Springer Nature Switzerland AG. Retrieved 2019-06-06.
  4. ^ "Palatin Technologies - PL-6983 for Female Sexual Dysfunction". 2015-05-26. Archived from the original on 2015-05-26.
[edit]